| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DEFB104A |
| Uniprot No | Q8WTQ1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-72aa |
| 氨基酸序列 | EFELDRICGY GTARCRKKCR SQEYRIGRCP NTYACCLRKW DESLLNRTKP |
| 预测分子量 | 6.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DEFB104A重组蛋白的模拟参考文献示例(注：以下内容为虚构，仅用于演示格式)：
---
1. **"Recombinant expression and antimicrobial characterization of human β-defensin DEFB104A"**
*Zhang, Y., et al. (2020)*
摘要：本研究在大肠杆菌系统中成功表达并纯化了重组DEFB104A蛋白，证实其对金黄色葡萄球菌和白色念珠菌具有显著抑制作用，提示其在抗感染治疗中的潜在应用。
2. **"DEFB104A modulates TLR4 signaling in macrophages via recombinant protein delivery"**
*Smith, J., & Lee, K. (2018)*
摘要：通过重组DEFB104A蛋白处理巨噬细胞，发现其通过TLR4通路抑制促炎因子IL-6和TNF-α的释放，为炎症性疾病的免疫调节机制提供了新见解。
3. **"Structural insights into DEFB104A by recombinant production and X-ray crystallography"**
*Wang, X., et al. (2021)*
摘要：利用昆虫细胞系统表达DEFB104A重组蛋白，并通过晶体学解析其三维结构，揭示了其独特的电荷分布与抗菌功能的关键结构域。
4. **"Optimization of DEFB104A recombinant production in mammalian expression systems"**
*Chen, L., et al. (2019)*
摘要：对比CHO和HEK293细胞中DEFB104A的表达效率，优化培养条件以提高蛋白产量和稳定性，为大规模生产奠定基础。
---
如需真实文献，建议通过PubMed或Google Scholar搜索关键词“DEFB104A recombinant protein”或“DEFB104A expression”。部分研究可能涉及其同源基因(如DEFB4/DEFB104)的功能探索。
DEFB104A (Defensin Beta 104A), also known as human β-defensin 4 (hBD-4), is a small cationic antimicrobial peptide belonging to the β-defensin family. These evolutionarily conserved proteins play critical roles in innate immunity, acting as host defense peptides against pathogens such as bacteria, fungi, and viruses. DEFB104A is encoded by the DEFB104 gene located on chromosome 8p23.1 and is primarily expressed in epithelial tissues, including the skin, respiratory tract, and urogenital system. Its expression can be upregulated in response to microbial invasion or proinflammatory cytokines, highlighting its role in bridging innate and adaptive immune responses.
Structurally, DEFB104A consists of approximately 50 amino acids, featuring six conserved cysteine residues forming three disulfide bonds that stabilize its β-sheet-rich fold. This compact structure enables interactions with microbial membranes, leading to membrane disruption and pathogen neutralization. Beyond direct antimicrobial activity, DEFB104A exhibits immunomodulatory functions, such as chemoattracting immune cells (e.g., dendritic cells and T lymphocytes) via chemokine receptors like CCR2 and CCR6.
Recombinant DEFB104A protein is produced using expression systems like *E. coli* or mammalian cell lines, often with tags for purification. Its recombinant form allows researchers to study its antimicrobial mechanisms, therapeutic potential, and role in inflammatory diseases. Studies suggest DEFB104A may have broader clinical relevance, including wound healing, combating antibiotic-resistant infections, and modulating mucosal immunity. However, challenges remain in optimizing its stability, minimizing cytotoxicity to host cells, and understanding tissue-specific regulatory pathways. Ongoing research explores its dual role as a microbicidal agent and immune regulator, positioning it as a promising candidate for developing novel antimicrobial or immunotherapeutic strategies.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
